<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Losartan</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00678</strong>&#160; (APRD00052)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Losartan is an angiotensin-receptor blocker (<span class="caps">ARB</span>) that may be used alone or with other agents to treat hypertension. Losartan and its longer acting metabolite, E-3174, lower blood pressure by antagonizing the renin-angiotensin-aldosterone system (<span class="caps">RAAS</span>); they compete with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (<span class="caps">ACE</span>) inhibitors, ARBs do not have the adverse effect of dry cough. Losartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of systolic dysfunction, myocardial infarction, coronary artery disease, and heart failure.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00678/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00678/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00678.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00678.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00678.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00678.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00678.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00678">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>DuP 89</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Losartan Potassium </strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000112/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000112/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: OXCMYAYHXIHQOA-UHFFFAOYSA-N</li>
              <li>Monoisotopic Mass: 460.118068924</li>
              <li>Average Mass: 461.001</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000112">DBSALT000112</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Cozaar</td><td>Merck &amp; Co.</td></tr><tr><td>Hyzaar</td><td>Merck &amp; Co.</td></tr><tr><td>Lortaan</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Anzaplus</td><td>Losartan + Hydrochlorothiazide</td></tr><tr><td>Hyzaar</td><td>Losartan + Hydrochlorothiazide</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antihypertensive-agents">Antihypertensive Agents</a></li>
<li><a href="/mesh/anti-arrhythmia-agents">Anti-Arrhythmia Agents</a></li>
<li><a href="/mesh/angiotensin-ii-type-1-receptor-blockers">Angiotensin II Type 1 Receptor Blockers</a></li>
<li><a href="/mesh/angiotensin-receptor-antagonists">Angiotensin Receptor Antagonists</a></li></ul></td></tr><tr><th>CAS number</th><td>114798-26-4</td></tr><tr><th>Weight</th><td>Average: 422.911<br>Monoisotopic: 422.162187095</td></tr><tr><th>Chemical Formula</th><td>C<sub>22</sub>H<sub>23</sub>ClN<sub>6</sub>O</td></tr><tr><th>InChI Key</th><td>PSIFNNKUMBGKDQ-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">[2-butyl-4-chloro-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazol-5-yl]methanol</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Azoles</td></tr><tr><th>Subclass</th><td>Tetrazoles</td></tr><tr><th>Direct parent</th><td>Biphenyltetrazoles and Derivatives</td></tr><tr><th>Alternative parents</th><td>Biphenyls and Derivatives; Aryl Chlorides; N-substituted Imidazoles; Primary Alcohols; Polyamines; Organochlorides; 1,2,4,5-trisubstituted Imidazoles</td></tr><tr><th>Substituents</th><td>biphenyl; 1,2,4,5-tetrasubstituted imidazole; aryl halide; benzene; n-substituted imidazole; aryl chloride; imidazole; polyamine; primary alcohol; organohalogen; organochloride; alcohol; organonitrogen compound; amine</td></tr><tr><th>Classification description</th><td>This compound belongs to the biphenyltetrazoles and derivatives. These are organic compounds containing a biphenyl attached to a tetrazole. A carbon atom of the biphenyl moiety is boned to a carbon or the nitrogen atom of the tetrazole moiety.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.</td></tr><tr><th>Pharmacodynamics</th><td>Losartan is the first of a class of antihypertensive agents called angiotensin II receptor blockers (ARBs). Losartan and its longer acting active metabolite, E-3174, are specific and selective type-1 angiotensin II receptor (AT1) antagonists which block the blood pressure increasing effects angiotensin II via the renin-angiotensin-aldosterone system (RAAS). RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from granular cells of the juxtaglomerular apparatus in the kidneys. Renin cleaves circulating angiotensinogen to angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to angiotensin II. Angiotensin II increases blood pressure by increasing total peripheral resistance, increasing sodium and water reabsorption in the kidneys via aldosterone secretion, and altering cardiovascular structure. Angiotensin II binds to two receptors: AT1 and type-2 angiotensin II receptor (AT2). AT1 is a G-protein coupled receptor (GPCR) that mediates the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Studies performed in recent years suggest that AT2 antagonizes AT1-mediated effects and directly affects long-term blood pressure control by inducing vasorelaxation and increasing urinary sodium excretion. Angiotensin receptor blockers (ARBs) are non-peptide competitive inhibitors of AT1. ARBs block the ability of angiotensin II to stimulate pressor and cell proliferative effects. Unlike ACE inhibitors, ARBs do not affect bradykinin-induced vasodilation. The overall effect of ARBs is a decrease in blood pressure.</td></tr><tr><th>Mechanism of action</th><td>Losartan competitively inhibits the binding of angiotensin II to AT1 in many tissues including vascular smooth muscle and the adrenal glands. Losartan is metabolized to its active metabolite, E-3174, which is 10 to 40 times more potent than losartan and acts as a non-competitive AT1 antagonist. Inhibition of angiotensin II binding to AT1 inhibits its AT1-mediated vasoconstrictive and aldosterone-secreting effects and results in decreased vascular resistance and blood pressure. Losartan is 1,000 times more selective for AT1 than AT2. Inhibition of aldosterone secretion may increase sodium and water excretion while decreasing potassium excretion. Losartan is effective for reducing blood pressure and may be used to treat essential hypertension, left ventricular hypertrophy and diabetic nephropathy.</td></tr><tr><th>Absorption</th><td>Losartan is well absorbed and undergoes substantial first-pass metabolism; the systemic bioavailability of losartan is approximately 33%. Mean peak concentrations of losartan and its active metabolite are reached in 1 hour and in 3-4 hours, respectively. While maximum plasma concentrations of losartan and its active metabolite are approximately equal, the AUC of the metabolite is about 4 times as great as that of losartan. When given with a meal, absorption is slows down and Cmax decreases. </td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>34 L [losartan, healthy subjects]</li>
	<li>12 L [active metabolite, healthy subjects]</li>
</ul></td></tr><tr><th>Protein binding</th><td>99.7% protein bound, primarily to albumin</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. Losartan is metabolized to a 5-carboxylic acid derivative (E-3174) via an aldehyde intermediate (E-3179) primarily by cytochrome P450 (CYP) 2C9 and CYP3A4. E-3174 is an active metabolite with 10- to 40-fold higher potency than its parent compound, losartan. Approxiamtely 14% of losartan is converted to E-3174; however, the AUC of E-3174 was found to be 4- to 8-fold higher than losartan and E-3174 is considered the main contributor to the pharmacologic effects of this medication. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Losartan</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00009">E-3179</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/9">Details</a></td></tr><tr><td>Losartan</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003541" target="_blank">UDP-glucuronosyltransferase 1-1</a></li>
<li><a href="/biodb/bio_entities/BE0003677" target="_blank">UDP-glucuronosyltransferase 1-3</a></li>
<li><a href="/biodb/bio_entities/BE0003678" target="_blank">UDP-glucuronosyltransferase 1-10</a></li>
<li><a href="/biodb/bio_entities/BE0003679" target="_blank">UDP-glucuronosyltransferase 2B7</a></li>
<li><a href="/biodb/bio_entities/BE0003680" target="_blank">UDP-glucuronosyltransferase 2B17</a></li></ul></td><td><a href="/metabolites/DBMET00010">Losartan N2-glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/10">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00009">E-3179</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00303">E-3174</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1047">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Following oral administration of losartan, 35% of the dose is recovered in the urine and about 60% in the feces. Following an intravenous dose, 45% is recovered in the urine and 50% in the feces. </td></tr><tr><th>Half life</th><td>The terminal t<sub>1/2</sub> of losartan is 2 hours. The active metabolite has a half-life of 6-9 hours. </td></tr><tr><th>Clearance</th><td><ul>
	<li>Total plasma clearance = 600 mL/min [losartan]</li>
	<li>Total plasma clearance = 50 mL/min [active metabolite]</li>
	<li>Renal clearance = 75 mL/min [losartan]</li>
	<li>Renal clearance = 25 mL/min [active metabolite]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Hypotension and tachycardia; Bradycardia could occur from parasympathetic (vagal) stimulation, LD<sub>50</sub>= 1000 mg/kg (orally in rat)</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Losartan Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.7812</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.8957</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6993</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8782</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.5309</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5689</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.6839</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9115</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6226</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.5514</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5423</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8102</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.6288</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.796</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.7049</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.5382
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.6595
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.6055 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Strong inhibitor 
        </td>
        <td>
            0.5781
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.8084
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Merck research laboratories div merck co inc</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Merck &amp; Co., Inc.</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.aqpharmaceuticals.com">AQ Pharmaceuticals Inc.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.bms.com">Bristol-Myers Squibb Co.</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.ipcalabs.com">Ipca Laboratories Ltd.</a></li>
<li>Kaiser Foundation Hospital</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.merck.com">Merck &amp; Co.</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li>Neuman Distributors Inc.</li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li><a href="http://www.roxane.com">Roxane Labs</a></li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.torrentpharma.com">Torrent Pharmaceuticals</a></li>
<li>Vangard Labs Inc.</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>25 mg, 50 mg, 100 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00594">Amiloride</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB01395">Drospirenone</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00328">Indomethacin</a></td><td>Indomethacin decreases the effect of losartan</td></tr><tr><td><a href="/drugs/DB00046">Insulin Lispro</a></td><td>Concomitant therapy with angiotensin II receptor blockers may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely. </td></tr><tr><td><a href="/drugs/DB01356">Lithium</a></td><td>Losartan increases serum levels of lithium</td></tr><tr><td><a href="/drugs/DB01345">Potassium</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB01369">Quinupristin</a></td><td>This combination presents an increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin decreases the effect of losartan</td></tr><tr><td><a href="/drugs/DB00421">Spironolactone</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00684">Tobramycin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01124">Tolbutamide</a></td><td>Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Losartan. Consider alternate therapy or monitor for changes in Losartan therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00519">Trandolapril</a></td><td>The angiotensin II receptor blocker, Losartan, may increase the adverse effects of Trandolapril. </td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. </td></tr><tr><td><a href="/drugs/DB00755">Tretinoin</a></td><td>The moderate CYP2C8 inhibitor, Losartan, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Losartan is initiated, discontinued to dose changed.</td></tr><tr><td><a href="/drugs/DB00384">Triamterene</a></td><td>Increased risk of hyperkalemia</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take without regard to meals. Take at same time each day. Food delays absorption, but does not affect the extent of absorption.</li></ul></td></tr></tbody></table>